REDWOOD CITY, Calif.,
Nov. 3, 2016 /PRNewswire/ -- Genomic
Health, Inc. (Nasdaq: GHDX) today announced that Brad Cole, chief
operating officer and chief financial officer, will present at the
Credit Suisse 25th Annual Healthcare Conference in
Scottsdale, Arizona on
Tuesday, November 8, 2016 at
3:30 p.m. Mountain Time.
To access the live and subsequently archived webcast of the
presentation, go to the Investor Relations section of the company's
web site at http://investor.genomichealth.com. Please connect to
the web site at least 15 minutes prior to the presentation to allow
for any software download that may be necessary. An archived replay
will be available for three months beginning 24 hours after the
live presentation.
About Genomic Health
Genomic Health, Inc.
(NASDAQ: GHDX) is the world's leading provider of genomic-based
diagnostic tests that help optimize cancer care by addressing the
overtreatment of the disease, one of the greatest issues in
healthcare today. With its Oncotype IQ™ Genomic Intelligence
Platform, the company is applying its world-class scientific and
commercial expertise and infrastructure to lead the translation of
clinical and genomic big data into actionable results for treatment
planning throughout the cancer patient journey, from diagnosis to
treatment selection and monitoring. The Oncotype IQ portfolio of
genomic tests and services currently consists of the company's
flagship line of Oncotype DX gene expression tests that have been
used to guide treatment decisions for more than 700,000 cancer
patients worldwide. Genomic Health is expanding its test portfolio
to include additional liquid- and tissue-based tests, including the
recently launched Oncotype SEQ® Liquid Select assay. The company is
based in Redwood City, California, with
international headquarters in Geneva, Switzerland. For
more information, please visit, www.GenomicHealth.com and
follow the company on
Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
and the other risks set forth in the company's filings with
the Securities and Exchange Commission, including the risks
set forth in the company's quarterly report on Form 10-Q for the
quarter ended June 30, 2016. These forward-looking statements
speak only as of the date hereof. Genomic
Health disclaims any obligation to update these
forward-looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX,
Recurrence Score, DCIS Score, Oncotype SEQ, and Oncotype IQ are
trademarks or registered trademarks of Genomic Health, Inc. All
other trademarks and service marks are the property of their
respective owners.
GHDX-F
Logo -
http://photos.prnewswire.com/prnh/20130425/SF01493LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/genomic-health-to-present-at-the-credit-suisse-25th-annual-healthcare-conference-300356553.html
SOURCE Genomic Health, Inc.